Skip to main content
. Author manuscript; available in PMC: 2023 Apr 19.
Published in final edited form as: Circulation. 2022 Feb 4;145(16):1218–1233. doi: 10.1161/CIRCULATIONAHA.121.056850

Figure 5. lncExACT1 works through DCHS2.

Figure 5.

A. QRT-PCR measurement of DCHS2 in hearts from HF patients and controls (n=12/group), and in mice with HF or lncExACT1 overexpression, or exercise (Run) or lncExACT1 inhibition (Gap). B. Luciferase activity driven by DCHS2 promotor fragments in NRVMs with lncExACT1 OE or KD. C. QRT-PCR measurement with primers targeting different regions of DCHS2 promoter in complex from pulldown with probes targeting sense and antisense sequence of lncExACT1. D. Quantification of EdU and troponin double-positive cardiomyocytes by flow cytometry. E. Quantification of cardiomyocyte size in NRVMs treated with scrambled control or DCHS2 siRNA. F. QRT-PCR measurement of hypertrophy gene markers, n=3/group. G. Quantification of EdU positive cardiomyocytes by flow cytometry. H. Quantification of cardiomyocytes size after lncExACT1 OE and/or DCHS2 KD in NRVMs. *p<0.05, **p<0.01; in C and D, *p<0.05 vs. Control, #p<0.05 vs. lncExACT1 KD. A, C, D, and E by Student’s t test; B, F, G, and H by one-way analysis of variance (ANOVA) with post hoc Tukey. Data shown as mean±SEM.